苏州药明康德新药开发股份有限公司

What 苏州药明康德新药开发股份有限公司 does

WuXi AppTec (stock codes 603259.SH / 2359.HK) is a global Contract Research, Development and Manufacturing Organization (CRDMO) headquartered in Shanghai, China, with operational bases across Asia, Europe, and North America. The company provides integrated, end-to-end drug discovery, development, and manufacturing services to over 6,000 pharmaceutical and life sciences partners across more than 30 countries. Its business is organized under three core platforms: WuXi Chemistry (small molecule and oligonucleotide/peptide CRDMO services from discovery through commercial manufacturing), WuXi Biology (target discovery, candidate screening, in vivo and in vitro pharmacology), and WuXi Testing (drug safety evaluation, DMPK, and preclinical services compliant with FDA, OECD, NMPA, and PMDA standards). The company also operates LabNetwork as a compound library and screening service platform.

The core operating model is the integrated CRDMO platform executed through a "follow the molecule" and "win the molecule" strategy, where client assets progress through research, development, and manufacturing within a single provider. WuXi AppTec maintains a small molecule D&M pipeline of 3,550 molecules as of March 2026 (89 commercial, 94 Phase III, 386 Phase II, 2,981 preclinical/Phase I), supported by 4,000+kL of API reactor capacity and 100,000+L of peptide solid-phase synthesis reactor capacity. Revenue is generated primarily through fee-for-service contracts with global pharma and biotech customers of all sizes (horizontal segmentation). FY2025 continuing operations revenue was 434.2亿元 CNY (+21.4% YoY) with adjusted non-IFRS net profit of 149.6亿元 (+41.3% YoY) and adjusted operating cash flow of 166.7亿元 (+39.1% YoY). Order backlog from continuing operations reached 580亿元 at end-2025 (+28.8% YoY) and 597.7亿元 by March 2026 (+23.6% YoY).

The company was founded in 2000, completed its A-share IPO on the Shanghai Stock Exchange in May 2018 and its H-share listing in Hong Kong in December 2018. It is led by Chairman & CEO Ge Li (李革) and Co-CEO Yang Qing (杨青). Facilities in Changzhou, Taixing, and Jinshan passed FDA inspections with zero observations in 2025, and all 20 operational bases hold ISO/IEC 27001 certification. ESG credentials include MSCI AAA (first time, 2025), CDP double-A on climate and water (2025), inclusion in the Dow Jones Best-in-Class World Index (2026), FTSE4Good (four consecutive years), EcoVadis Gold (second consecutive year), and SBTi-verified GHG targets. The company is the recipient of Frost & Sullivan's Global CRDMO Company of the Year award for nine consecutive years.

Name

苏州药明康德新药开发股份有限公司

Legal name

无锡药明康德新药开发股份有限公司 (Wuxi AppTec Co., Ltd.)

Website

https://wuxiapptec.com.cn

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

Global CRDMO platform providing integrated drug discovery, development, and manufacturing services to over 6,000 pharmaceutical and life sciences partners across 30+ countries through WuXi Chemistry, WuXi Biology, and WuXi Testing; operates a 3,550-molecule small molecule pipeline.

Ownership category

akta.pro rank

Product category

Contract Research, Development and Manufacturing (CRDMO) Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG)

Keywords

• Contract research services
• Drug development services
• Pharmaceutical manufacturing
• CRDMO services
• Oligonucleotide manufacturing

Headquarters

HQ city

苏州市, 江苏省

HQ country

China

HQ region

Asia

Offices11 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Research and Development Services: Fee-for-service model providing drug discovery, development and manufacturing services to pharmaceutical companies. Revenue derived from Chemistry (WuXi Chemistry), Biology (WuXi Biology), and Testing (WuXi Testing) business units. Revenue is project-based and service-based with 'follow the molecule' strategy driving molecule progression through pipeline.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

WuXi AppTec provides integrated Contract Research, Development and Manufacturing Organization (CRDMO) services to global pharmaceutical and life sciences companies, covering the full drug lifecycle from chemical drug discovery research and biology services through clinical development to commercial manufacturing of small molecule drugs, oligonucleotides and peptides. The company operates through three core platforms — WuXi Chemistry, WuXi Biology, and WuXi Testing — under a unified 'follow the molecule' strategy that progresses client molecules from preclinical stages through commercialization.

Product overview

WuXi AppTec operates a unified CRDMO (Contract Research, Development and Manufacturing Organization) platform that integrates three core service divisions: WuXi Chemistry for end-to-end small molecule and oligonucleotide/multiple peptide drug development and manufacturing, WuXi Biology for comprehensive drug discovery biology services, and WuXi Testing for full-lifecycle drug R&D testing solutions including safety evaluation and DMPK. The company also operates LabNetwork as a compound library service platform. The CRDMO business model follows a 'follow the molecule' strategy, where the platform drives continuous growth by efficiently converting pipeline molecules from research through development to commercial manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• WuXi Chemistry: Chemical business platform providing CRDMO services from drug discovery to commercial manufacturing
• WuXi Biology
• WuXi Testing
• TIDES

Products and services

• CRDMO Integrated Platform (一体化端到端平台) Integrated Contract Research, Development and Manufacturing Organization platform that combines research, development and manufacturing capabilities to provide end-to-end drug development services from discovery through commercial manufacturing for global pharmaceutical and biotech companies.
• WuXi Chemistry (化学业务平台) Provides end-to-end CRDMO services from chemical drug discovery research to commercial manufacturing, supporting small molecule and oligonucleotide/multiple peptide drug development for global pharmaceutical and biotech clients. The platform manages a small molecule D&M pipeline of 3,550 molecules including 89 commercial projects, 94 Phase III, 386 Phase II and 2,981 preclinical/Phase I projects.
• WuXi Biology (生物学业务平台) Offers comprehensive biology services and solutions supporting target discovery to clinical candidate selection, including integrated in-vivo and in-vitro projects with in vivo pharmacology and in vitro screening platforms for global pharmaceutical and biotech customers.
• WuXi Testing (测试业务平台) Provides full-lifecycle integrated drug R&D testing solutions under FDA, OECD, NMPA and PMDA compliant quality standards, including drug safety evaluation and DMPK (Drug Metabolism and Pharmacokinetics) services for pharmaceutical and biotech clients globally.
• TIDES Business (Oligonucleotide and Peptide Manufacturing) Oligonucleotide and peptide drug development and manufacturing services utilizing 100,000+ L solid-phase synthesis reactor capacity, serving pharmaceutical and biotech clients with rapidly growing demand for oligonucleotide and peptide therapeutics, with revenue growth exceeding 96% YoY.
• LabNetwork (览博网) Compound Library Service Platform One-stop compound library service platform providing compound library design, search, ordering and screening services with integrated biology screening capabilities including biochemical activity testing, cell activity testing, and protein production for pharmaceutical and biotech researchers.

Quantifiable outcome

• 3,550 small molecule D&M pipeline molecules as of March 2026, with 89 commercial projects
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered strategic and core.

• NEOM (沙特新未来城)strategicStrategic or Co-development Partner · 28 October 2025WuXi AppTec signed strategic cooperation memoranda with NEOM (Saudi Arabia's sustainable city project in the northwestern region) and Saudi Arabia's Ministry of Health to explore expanding CRDMO platform services in the region.
• Saudi Arabia Ministry of HealthstrategicStrategic or Co-development Partner · 28 October 2025Strategic cooperation memorandum signed to explore bringing WuXi AppTec's integrated CRDMO services to Saudi Arabia in collaboration with the national healthcare system.
• United Nations Global Compact (UNGC)coreStrategic or Co-development PartnerWuXi AppTec joined the UN Global Compact, committing to support its ten principles covering human rights, labor, environment, and anti-corruption.
• Pharmaceutical Supply Chain Initiative (PSCI)coreStrategic or Co-development PartnerWuXi AppTec joined PSCI as a supplier partner, demonstrating commitment to responsible pharmaceutical supply chain practices.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Pharmaron: China-based CRO/CDMO providing discovery, preclinical and manufacturing services. Most comparable China-based peer to WuXi with similar end-to-end service model but smaller scale.
• Asymchem: China-headquartered CDMO specializing in small molecule API and intermediates manufacturing. Comparable to WuXi Chemistry and WuXi STA on small molecule manufacturing, with a narrower scope.

Direct peers

• Charles River Laboratories: Global CRO/CDMO offering discovery and safety assessment services plus CDMO capabilities. Most directly comparable end-to-end early-stage research peer to WuXi's integrated CRDMO platform.
• Lonza Group: World's largest CDMO with leading biologics and small molecule capacity. Comparable to WuXi across CDMO scale and modality breadth, with deeper biologics exposure and European footprint.
• Catalent: Major CDMO providing drug substance, drug product and biologic fill-finish services. Closely comparable to WuXi's small molecule and biologics manufacturing offerings, though with stronger formulation/fill-finish depth.
• Samsung Biologics: Asia-headquartered large-scale biologics CDMO. Comparable to WuXi in CDMO scale and global pharma customer base, with biologics-focused capabilities versus WuXi's broader CRDMO scope.

Broad incumbents

• IQVIA: Largest global CRO with deep clinical and real-world evidence offerings. Comparable to WuXi for clinical-stage drug development services, though IQVIA is broader and CRO-led rather than CDMO-led.
• ICON plc: Major global CRO providing clinical research and laboratory services. Overlaps with WuXi Testing and clinical-stage capabilities, particularly for global pharma sponsors.
• Thermo Fisher Scientific (PPD): Diversified life sciences tools and CRO/CDMO incumbent through PPD. Overlaps with WuXi across clinical research services and pharma manufacturing, but as one division within a much larger tools-led portfolio.

Others

• Bio-Techne: Supplies reagents, proteins and analytical tools used across drug discovery and development. Adjacent rather than directly competing, but serves many of the same pharma and biotech customers as WuXi Biology and WuXi Testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/%E8%8B%8F%E5%B7%9E%E8%8D%AF%E6%98%8E%E5%BA%B7%E5%BE%B7%E6%96%B0%E8%8D%AF%E5%BC%80%E5%8F%91%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 苏州药明康德新药开发股份有限公司